{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_16", "document_index": 84, "latency_s": 0.7780542999971658, "prompt_toks": 6422, "completion_toks": 80, "relevance_score": 0.0036642202}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    United States: Cannabidiol is legal under the 2018 Farm Bill[37]. The rest of the cannabis plant (anything with more than 0.3% Delta-9-THC) is still under Schedule I of the Controlled Substances Act.[citation needed]\n\nExternal links\n\nCannabidiol (Wikipedia)\n\nCannabidiol (Isomer Design)\n\nCannabidiol (Drugs-Forum)\n\nProject CBD\n\nLiterature\n\nMechoulam, R., Peters, M., Murillo-Rodríguez, E., & Hanuš, L.O. (2007). Cannabidiol--recent advances. Chemistry & Biodiversity, 4 8, 1678-92.\n\nMechoulam, R., Parker, L. A., & Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects. The Journal of Clinical Pharmacology, 42(S1).\n\nDevinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., ... & Martinez‐Orgado, J. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802. https://doi.org/0.1111/epi.12631\n\nReferences\n\n\n                    Context: \n                    This chunk provides information on the legal status of cannabidiol in the United States, highlighting its legality under the 2018 Farm Bill and its classification under Schedule I of the Controlled Substances Act. It also includes external links and key literature references relevant to cannabidiol research and regulation, complementing the overall focus on CBD's effects, safety, and legal considerations within the full document.\n                "}
{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_2", "document_index": 84, "latency_s": 0.9733628999965731, "prompt_toks": 6309, "completion_toks": 77, "relevance_score": 0.0031480708}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    Cannabidiol can be administered by multiple routes, including by inhalation of cannabis smoke or vapor, as an aerosol spray into the cheek, and by mouth. It may be supplied as CBD oil containing only CBD as the active ingredient (i.e. no added THC or terpenes), a full-plant CBD-dominant hemp extract oil, capsules, dried cannabis, or as a prescription liquid solution.[2]\n\nIn the United States, the cannabidiol drug Epidiolex is approved by the Food and Drug Administration for the treatment of epilepsy disorders.[3] The U.S. Drug Enforcement Administration has assigned Epidiolex a Schedule V classification, while non-Epidiolex CBD remains a Schedule I drug prohibited for any use.[4] Cannabidiol is not scheduled under any United Nations drug control treaties.[5]\n\nSubjective effects include anxiety suppression, muscle relaxation, and pain relief.\n\n\n                    Context: \n                    This excerpt details the common administration routes, legal status, and subjective effects of cannabidiol (CBD), highlighting specific preparations such as oils and prescription pharmaceuticals like Epidiolex. It provides essential information on legal classifications in the U.S. and the typical psychoactive effects experienced, situating it within the broader discussion of CBD’s pharmacology, medical use, and legal considerations.\n                "}
{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_24", "document_index": 84, "latency_s": 1.3235749000014039, "prompt_toks": 6478, "completion_toks": 106, "relevance_score": 0.0027362213}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    \"Cannabis study reveals how CBD offsets the psychiatric side-effects of THC\". ScienceDaily (Press release). September 30, 2019.\n\n↑ https://www.scielo.br/j/bjmbr/a/5sGSHxqFkYHxCYhRZh6fWKH/?format=pdf&lang=en. Missing or empty |title= (help)\n\n↑ Czégény, Z; Nagy, G; Babinszki, B; Bajtel, Á; Sebestyén, Z; Kiss, T; Csupor-Löffler, B; Tóth, B; Csupor, D (26 April 2021). \"CBD, a precursor of THC in e-cigarettes\". Scientific reports. 11 (1): 8951. doi:10.1038/s41598-021-88389-z. PMC 8076212 Check |pmc= value (help). PMID 33903673.\n\n↑ Englund, A., Oliver, D., Chesney, E., Chester, L., Wilson, J., Sovi, S., De Micheli, A., Hodsoll, J., Fusar-Poli, P., Strang, J., Murray, R. M., Freeman, T. P., McGuire, P. (16 November 2022). \"Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios\". Neuropsychopharmacology: 1–8. doi:10.1038/s41386-022-01478-z. ISSN 1740-634X. Retrieved 25 November 2022.\n\n\n                    Context: \n                    This excerpt highlights recent research on how cannabidiol (CBD) can counteract the psychiatric side effects of THC, including findings from a 2019 ScienceDaily article and a 2022 neuropsychopharmacology study examining different CBD:THC ratios to improve cannabis safety. It provides scientific evidence supporting CBD's role in modulating THC's adverse effects, relevant to the document's overview of CBD's pharmacology, effects, and harm reduction potential. The references emphasize CBD’s potential to influence cannabis-related mental health outcomes.\n                "}
